Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology shared a post on X:
“Sat in on a sharp panel at NPC 2026 in Nashville with Charles Simone II, J. Isabelle Choi, Robert H. Press, Annemarie Shepherd, and Curtiland Deville on the challenges: trial complexity, funding gaps, and an OS endpoint that may never move in a local therapy trial.
Composite endpoints (DFS + toxicity) capture what protons actually do for patients. And embedding proton arms in photon trials as secondary comparisons are potential practical paths forward in the field.”
Other articles about NPC on OncoDaily.
